Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PiVOT: GMRx-4 Polypill vs Metformin in New Onset Type 2 Diabetes
NCT05833958Phase 2Withdrawn
- Sponsor
- George Medicines
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of dapagliflozin + sitagliptin + metformin in type 2 diabetes mellitus (T2DM), sponsored by George Medicines. Planned start Sep 2024; status: withdrawn.
02
Drugs
dapagliflozin + sitagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05833958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833958.